TY - JOUR
T1 - Impaired default network functional connectivity in autosomal dominant Alzheimer disease
AU - Chhatwal, Jasmeer P.
AU - Schultz, Aaron P.
AU - Johnson, Keith
AU - Benzinger, Tammie L.S.
AU - Jack, Clifford
AU - Ances, Beau M.
AU - Sullivan, Caroline A.
AU - Salloway, Stephen P.
AU - Ringman, John M.
AU - Koeppe, Robert A.
AU - Marcus, Daniel S.
AU - Thompson, Paul
AU - Saykin, Andrew J.
AU - Correia, Stephen
AU - Schofield, Peter R.
AU - Rowe, Christopher C.
AU - Fox, Nick C.
AU - Brickman, Adam M.
AU - Mayeux, Richard
AU - McDade, Eric
AU - Bateman, Randall
AU - Fagan, Anne M.
AU - Goate, Allison M.
AU - Xiong, Chengjie
AU - Buckles, Virginia D.
AU - Morris, John C.
AU - Sperling, Reisa A.
PY - 2013/8/20
Y1 - 2013/8/20
N2 - Objective: To investigate default mode network (DMN) functional connectivity MRI (fcMRI) in a large cross-sectional cohort of subjects from families harboring pathogenic presenilin-1 (PSEN1), presenilin- 2 (PSEN2), and amyloid precursor protein (APP)mutations participating in the Dominantly Inherited Alzheimer Network. Methods: Eighty-three mutation carriers and 37 asymptomatic noncarriers from the same families underwent fMRI during resting state at 8 centers in the United States, United Kingdom, and Australia. Using group-independent component analysis, fcMRI was compared using mutation status and Clinical Dementia Rating to stratify groups, and related to each participant's estimated years from expected symptom onset (eYO). Results: We observed significantly decreased DMN fcMRI in mutation carriers with increasing Clinical Dementia Rating, most evident in the precuneus/posterior cingulate and parietal cortices (p , 0.001). Comparison of asymptomatic mutation carriers with noncarriers demonstrated decreased fcMRI in the precuneus/posterior cingulate (p 5 0.014) and right parietal cortex (p 5 0.0016). We observed a significant interaction between mutation carrier status and eYO, with decreases in DMN fcMRI observed as mutation carriers approached and surpassed their eYO. Conclusion: Functional disruption of the DMN occurs early in the course of autosomal dominant Alzheimer disease, beginning before clinically evident symptoms, and worsening with increased impairment. These findings suggest that DMN fcMRI may prove useful as a biomarker across a wide spectrum of disease, and support the feasibility of DMN fcMRI as a secondary endpoint in upcoming multicenter clinical trials in Alzheimer disease.
AB - Objective: To investigate default mode network (DMN) functional connectivity MRI (fcMRI) in a large cross-sectional cohort of subjects from families harboring pathogenic presenilin-1 (PSEN1), presenilin- 2 (PSEN2), and amyloid precursor protein (APP)mutations participating in the Dominantly Inherited Alzheimer Network. Methods: Eighty-three mutation carriers and 37 asymptomatic noncarriers from the same families underwent fMRI during resting state at 8 centers in the United States, United Kingdom, and Australia. Using group-independent component analysis, fcMRI was compared using mutation status and Clinical Dementia Rating to stratify groups, and related to each participant's estimated years from expected symptom onset (eYO). Results: We observed significantly decreased DMN fcMRI in mutation carriers with increasing Clinical Dementia Rating, most evident in the precuneus/posterior cingulate and parietal cortices (p , 0.001). Comparison of asymptomatic mutation carriers with noncarriers demonstrated decreased fcMRI in the precuneus/posterior cingulate (p 5 0.014) and right parietal cortex (p 5 0.0016). We observed a significant interaction between mutation carrier status and eYO, with decreases in DMN fcMRI observed as mutation carriers approached and surpassed their eYO. Conclusion: Functional disruption of the DMN occurs early in the course of autosomal dominant Alzheimer disease, beginning before clinically evident symptoms, and worsening with increased impairment. These findings suggest that DMN fcMRI may prove useful as a biomarker across a wide spectrum of disease, and support the feasibility of DMN fcMRI as a secondary endpoint in upcoming multicenter clinical trials in Alzheimer disease.
UR - http://www.scopus.com/inward/record.url?scp=84884493007&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3182a1aafe
DO - 10.1212/WNL.0b013e3182a1aafe
M3 - Article
C2 - 23884042
AN - SCOPUS:84884493007
SN - 0028-3878
VL - 81
SP - 736
EP - 744
JO - Neurology
JF - Neurology
IS - 8
ER -